Drugs / fesomersen
fesomersen
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04534114 | Sep 2020 → Jan 2022 | end stage renal failure | Bayer | Completed | Missed primary |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-07-28 | Bayer | Phase 2b studies of investigational selective coagulation modulators fesomersen and osocimab in patients with advanced renal disease completed bayer.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | fesomersen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04534114 ↗ |
| Known as | BAY2976217 | “Fesomersen sodium (BAY2976217)” NCT04534114 ↗ |
| Known as | Fesomersen sodium | “Fesomersen sodium (BAY2976217)” NCT04534114 ↗ |
| Action | Inhibit | “an inhibitor of hepatic Factor XI expression” PMID 38537676 ↗ Mar 2024 |
| Modality | Antisense oligonucleotide | “fesomersen, an antisense oligonucleotide” PMID 38906653 ↗ Jul 2024 |
| Route | Subcutaneous | “Study intervention will be injected subcutaneously.” NCT04534114 ↗ |